Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPERO long-term extension study of tozorakimab in COPD with exacerbation history
2022-501063-41-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tozorakimab with Tozorakimab placebo (2 arms). Primary endpoint: Annualised rate of severe COPD exacerbation in former smokers. Started Mar 2023; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2022-501063-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501063-41-00.